About
Professor Bahl is an internationally renowned expert on all aspects of prostate cancer treatment and can discuss the intricacies of the new modalities of treatment including IMRT, proton therapy, single modality HDR brachytherapy, enabling patients to come to an informed decision, knowing they are in the most expert hands. Professor Bahl has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country.
Prior to Professor Bahl's current roles, he became member of the Royal College of Physicians (UK) and trained in clinical oncology, achieving the fellowship of the Royal College of Radiologists qualification, he has also been awarded the fellowship of the Royal College of Physicians and is a current member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer and chair the penile cancer subgroup. Professor Bahl has been college tutor of the Royal College of Radiologists for 10 years and has supervised several MD theses in breast and prostate cancer research. He has previously been in the NCRI renal and prostate clinical studies group. He is an Executive Committee member of the British Uro-oncology Group.
In addition to his extensive qualifications, Professor Bahl is also actively involved in research into breast, prostate, bladder and penile cancers and has more than 100 publications in these research areas and has several presentations at national and international meetings. In 2012, he was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London and is a Visiting Professor to two international centres and at the University of West of England. He currently holds research grants in excess of £2million and is Chief Investigator for several multicentre trials including ATLAS, CONCEPT and ACE which are focusing on new modalities of treatment in breast and prostate cancer and is also leading the robotic brachytherapy project. Professor Bahl is at the forefront of medical research and there are few doctors better qualified than him.
Professor Bahl is currently Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol with a special interest in breast and urological cancers as well Research lead for uro-oncology at Bristol Haematology and Oncology Centre. Led and developed the prostate brachytherapy service at Bristol. He is the head of oncology at Spire Bristol and Clinical Director at GenesisCare Bristol; the centres are lucky to have such an internationally renowned professional as their director.
Diseases, Medical Tests and TreatmentsRadiotherapy
Chemotherapy
IMRT
Proton therapy
Single modality
HDR brachytherapy
Bladder cancer,
Breast cancer,
Genito-urinary cancer,
Kidney cancer
Prostate cancer
Prior to Professor Bahl's current roles, he became member of the Royal College of Physicians (UK) and trained in clinical oncology, achieving the fellowship of the Royal College of Radiologists qualification, he has also been awarded the fellowship of the Royal College of Physicians and is a current member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer and chair the penile cancer subgroup. Professor Bahl has been college tutor of the Royal College of Radiologists for 10 years and has supervised several MD theses in breast and prostate cancer research. He has previously been in the NCRI renal and prostate clinical studies group. He is an Executive Committee member of the British Uro-oncology Group.
In addition to his extensive qualifications, Professor Bahl is also actively involved in research into breast, prostate, bladder and penile cancers and has more than 100 publications in these research areas and has several presentations at national and international meetings. In 2012, he was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London and is a Visiting Professor to two international centres and at the University of West of England. He currently holds research grants in excess of £2million and is Chief Investigator for several multicentre trials including ATLAS, CONCEPT and ACE which are focusing on new modalities of treatment in breast and prostate cancer and is also leading the robotic brachytherapy project. Professor Bahl is at the forefront of medical research and there are few doctors better qualified than him.
Professor Bahl is currently Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol with a special interest in breast and urological cancers as well Research lead for uro-oncology at Bristol Haematology and Oncology Centre. Led and developed the prostate brachytherapy service at Bristol. He is the head of oncology at Spire Bristol and Clinical Director at GenesisCare Bristol; the centres are lucky to have such an internationally renowned professional as their director.
Diseases, Medical Tests and TreatmentsRadiotherapy
Chemotherapy
IMRT
Proton therapy
Single modality
HDR brachytherapy
Bladder cancer,
Breast cancer,
Genito-urinary cancer,
Kidney cancer
Prostate cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Professor Amit Bahl
Education & training
-
2011–2017 MD · Medicine and Surgery
-
2017–2021 Residency · Oncology
-
2021–2022 Fellowship · Subspecialty training
Career & appointments
-
2021-09–2022-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Allianz Professional · 4,000,000 EUR coverage · No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,217 |
| Annual physical exam | 99395 | 463 |
| Vaccination administration | 90471 | 1,375 |
| Minor procedure (skin) | 17110 | 72 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 30 min | in_clinic | 810.00 EUR |
| Minor procedure (skin) | 120 min | in_clinic | 540.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 6 · i10: 12
-
European registry analysis of Oncology outcomes
DOI: 10.4986/euroclin.2025.0 · PMID: 37120137 · cited by 65
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.6826/euroclin.2024.1 · PMID: 32426581 · cited by 27
-
European registry analysis of Oncology outcomes
DOI: 10.2881/euroclin.2023.2 · PMID: 39386194 · cited by 125
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · Bristol · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — Bristol · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · Since 2022
- national college of family doctors — Member · Since 2022
- European Union of Medical Specialists (UEMS) — Member · Since 2022
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · dr.amit.bahl@euroclinics.example
- Accepted international insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
Location
1 tagPatient reviews
26 verified reviews5.00
★★★★★
26 reviews
- Bedside Manner
- 5.0
- Knowledge
- 5.0
- Wait Time
- 4.8
- Staff Friendliness
- 5.0
- Ease Of Appointment
- 4.9
- Value For Money
- 4.9
- Would Recommend Pct
- 99.0
Share your experience — help other patients find the right doctor. Write a review →
Recent reviews
-
★★★★★ ✓ Verified Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Verified Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Verified Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
